SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT.Chronic illness · 2023Trial
- A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.The oncologist · 2020Trial
- Multidisciplinary Strategies to Manage Treatment-Related Dermatologic Toxicity and Improve Quality of Life in Cancer Patients: A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- Patient-Reported Outcomes on Quality of Life in Older Adults with Oral Pemphigus.Healthcare (Basel, Switzerland) · 2025Article
- Psychometric evaluations of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitors 18 (FACT-EGFRI-18-sC) for measuring dermatologic toxicities in metastatic colorectal cancer patients treated with EGFRIs.Health and quality of life outcomes · 2025Article
- Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.International journal of women's dermatology · 2021Review
- Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Adverse events of targeted therapies reported by patients with cancer treated in primary care.The European journal of general practice · 2020Article
- Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study.Drugs in context · 2020Article
- Pruritus in patients with solid tumors: an overlooked supportive care need.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Quality of life and clinical and demographic characteristics of patients with cutaneous squamous cell carcinoma submitted to tumor resection by double-bladed scalpel.Anais brasileiros de dermatologia · 2019Article
- The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study.Cancer research and treatment · 2018Article
- Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.The oncologist · 2017Review
- Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.The oncologist · 2016Review
- Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand-Foot Syndrome.Asia-Pacific journal of oncology nursingArticle
- Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
purposeDermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.
methodsA comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments.
resultsThirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index (DLQI), and DIELH-24) and two were symptom-specific (functional assessment of cancer therapy-epidermal growth factor receptor inhibitor-18 (FACT-EGFRI-18) and hand-foot syndrome 14 (HFS-14)).
conclusionsWhile there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.